Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma

Inclusion Criteria: * Histologic diagnosis of nasopharyngeal carcinoma * Range from 18～69 years old * T3-4，N0-2，M0 (AJCC 2009) * KPS ≥ 80 * Nonmetastatic diseases * WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L * ALT or AST \< 1.5×ULN、bilirubin \< 1.5×ULN * 0Serum creatinine \< 1.5×ULN Exclusion Criteria: * Distance metastases * Previously treated (surgery，chemotherapy, radiation therapy，EGFR targeted therapy or immunotherapy) * Second malignancy within 5 years * Precious therapy with an investigational agent * Uncontrolled seizure disorder or other serious neurologic disease * ≥ Grade Ш allergic reaction to any drug including in this study * Clinically significant cardiac or respiratory disease * Creatinine clearance \< 30ml/min * Drug or alcohol addition * Do not have full capacity for civil acts * Severe complication, active infection * Concurrent immunotherapy or hormone therapy for other diseases * Pregnancy or lactation